News - Amgen, Rare diseases


Current filters:

AmgenRare diseases

Popular Filters

SOBI restructures Kineret and Kepivance deals


Swedish Orphan Biovitrum (STO: SOBI) said this morning that it has acquired the full rights to develop…

AmgenAnti-Arthritics/RheumaticsBiotechnologyKepivanceKineretLicensingOncologyPharmaceuticalRare diseasesSwedish Orphan Biovitrum

Licensing deals for Amgen/ImmunoGen and Shire/Arrowhead


US biotechnology company ImmunoGen (Nasdaq), which develops anticancer therapeutics using its Targeted…

AmgenArrowhead ResearchBiotechnologyImmunoGenLicensingOncologyPharmaceuticalRare diseasesShire

Kineret halts organ damage in inflammatory genetic disorder


A new study shows that Kineret (anakinra), a drug developed by US biotech giant Amgen (Nasdaq: AMGN)…

AmgenBiotechnologyKineretPharmaceuticalRare diseasesResearch

FDA eases REMS requirements for Amgen’s Nplate and GSK’s Promacta


The US Food and Drug Administration says that an agency initiated review of the current information has…

AmgenBiotechnologyGlaxoSmithKlineNorth AmericaNplatePharmaceuticalPromactaRare diseasesRegulation

Regulatory updates for Incivek, Xgeva and Corlux in North America


In a batch of regulatory news released yesterday, Vertex Pharmaceuticals (Nasdaq: VRTX) said that Health…

AmgenAnti-viralsCorcept TherapeuticsCorluxIncivekNorth AmericaPharmaceuticalRare diseasesRegulationVertexXgeva

Back to top